QED Pharmaceutical Services picks SAS® Clinical Data Integration to help clients implement CDISC standards

(QED levels the playing field for small drug developers seeking partnerships with large pharmaceutical companies)
Mumbai, 29th June, 2010 – SAS, the leader in business analytics software and services, announces today that QED Pharmaceutical Services has licensed SAS® Clinical Data Integration to enable its drug development clients to more easily form partnerships with key biopharmaceutical companies. The win at QED, a global contract research organization (CRO) with offices in India and the United States, continues the strong market momentum for SAS Clinical Data Integration. SAS, the leader in business analytics software and services, offers a comprehensive portfolio of life sciences software solutions for pharmaceutical, biotechnology and medical device companies.
“The availability of SAS Clinical Data Integration has made it possible for QED to efficiently implement complex data standards such as the CDISC standards,” said Dr. Ramana Kuchibhatla, QED founder. “This allows us to help our clients - predominantly small and sometimes virtual biopharmaceutical companies - achieve important milestones despite their size. Compliance with the latest CDISC standards makes growing drug developers like our clients very attractive partners to large pharma companies that are looking to in-license successful drug development programs. The overall value created by SAS Clinical Data Integration to both QED as a service company and our clients by making them attractive partners and ensuring regulatory compliance is tremendous.”
Mr. Sudipta K Sen, Regional Director South-East Asia, CEO & MD SAS India says “We are happy to be associated with QED pharmaceutical. The new deployment strengthens our commitment as a partner to help organizations in taking accurate decisions and to create an impact on their business goals.”
QED also has uses other SAS products including SAS® Enterprise Business Intelligence. With the continuous knowledge base created by these systems, QED can offer cost-effective services for its clients. “It’s as if we have designed an efficient mechanical engine, and now, with little modification for each clinical trial, we can crank out CDISC-compliant data and get our clients’ datasets output in regulatory submission-ready formats,” said
Kuchibhatla.

About SAS
SAS is the leader in business analytics software and services, and the largest independent vendor in the business intelligence market. With innovative business applications supported by an enterprise intelligence platform, SAS helps customers at 45,000 sites improve performance and deliver value by making better decisions faster. Since 1976 SAS has been giving customers around the world The Power to Know.

About SAS India
SAS has been in India since 1997 and has two wholly owned subsidiaries in the country: SAS Institute (India) Pvt. Ltd. and SAS Research & Development. With a team of more than 600 technology and domain experts, SAS India operations are headquartered in Mumbai with regional offices in Bangalore, New Delhi and Pune. SAS works with organizations across Industries and offers them critical enterprise intelligence to fuel innovation and meet their business objectives. Information on SAS India operations can be found at www.sas.com/india

About QED Pharmaceutical Services
QED Pharmaceutical Services is a leading global Contract Research Organization (CRO) with offices in Hyderabad, India, and Research Triangle Park, North Carolina. QED specializes in conducting Phase I through Phase IV clinical trials and other clinical and regulatory research services that cater to biotechnology and pharmaceutical product development. QED was established in 2007 by Dr. Ramana Kuchibhatla. For more information about QED, visit http://www.qedpharma.com/

Varun Vishwanath
Mutual PR
202, Yashashree,
Bandra-Kurla Complex,
Bandra (E), Mumbai – 400 051.
India

This release was published on openPR.